This is a corrigendum to: João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filipattos, Ivana Ritter, Elke Schüler, Bettina J Kraus, Stuart J. Pocock, Stefan D. Anker, Milton Packer, Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled, European Heart Journal, 2022; ehac306, https://doi.org/10.1093/eurheartj/ehac306.
In the originally published version of this manuscript, affiliations for several authors were erroneous. The affiliations were given as follows:
João Pedro Ferreira1,2*, Faiez Zannad3,4, Javed Butler5, Gerasimos Filipattos6, Ivana Ritter7, Elke Schüler8, Bettina J Kraus7,9,10, Stuart J. Pocock11, Stefan D. Anker12, and Milton Packer13,14
1Université de Lorraine, Inserm, Centre d’Investigations Cliniques Plurithématique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France; 2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; 3Baylor Heart and Vascular Institute Dallas, TX, USA; 4Imperial College, London, UK; 5University of Mississippi Medical Center, Jackson, MS, USA; 6National and Kapodistrian University of Athens School of Medicine, Athens, Greece; 7Boehringer Ingelheim International GmbH, Ingelheim, Germany; 8mainanalytics GmbH, Sulzbach, Germany; 9Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; 10Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany; 11London School of Hygiene and Tropical Medicine, London, UK; 12Department of Cardiology (CVK) Berlin Institute of Health Center for Regenerative Therapies (BCRT) German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany; 13Baylor Heart and Vascular Institute Dallas, TX, USA; and 14Imperial College, London, UK
The affiliations have now been updated.